Candidate genes for type 2 diabetes

Reviews in Endocrine and Metabolic Disorders

Volumn 5, Issue 2, 2004, Pages 151-176

  Parikh, Hemang ^a   Groop, Leif ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Candidate genes; Insulin deficiency; Insulin resistance; Meta analysis; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FIBRIC ACID DERIVATIVE; INSULIN; ISOPRENALINE; METFORMIN; SULFONYLUREA;

ANTIHYPERTENSIVE ACTIVITY; FATTY ACID METABOLISM; GENE CONTROL; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; INSULIN RESISTANCE; LIPOLYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; HUMANS; INSULIN; ISLETS OF LANGERHANS; LIPOLYSIS;

EID: 3543008338     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:REMD.0000021437.46773.26     Document Type: Review

References (237)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-787.
2. Groop LC, Tuomi T. Non-insulin-dependent diabetes mellitus - A collision between thrifty genes and an affluent society. Ann Med 1997;29:37-53.
3. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003;33:177-182.
4. Neel V. Diabetes mellitus: A "thrifty" genotype rendered detrimental by progress? Am J Hum Genet 1962:14.
5. Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 1994;94:1714-1721.
6. Emorine L, Marullo S, Briend-Sutren M, Patey G, Tate K, Delavier-Klutchko C, Strosberg A. Molecular characterization of the human beta-3-adrenergic receptor. Science 1989;245:1118-1121.
7. Walston J, Silver K, Bogardus C, Knowler W, Celi F, Austin S, Manning B, Strosberg D, Stern M, Raben N, Sorkin J, Roth J, Shuldiner A. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta3-adrenergic-receptor gene. New Engl J Med 1995;333:343-347.
8. Widen E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC. Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995;333:348-351.
9. Clement K, Vaisse C, Manning BS, Basdevant A, Guy-Grand B, Ruiz J, Silver KD, Shuldiner AR, Froguel P, Strosberg AD. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 1995;333:352-354.
10. Sipiläinen R, Uusitupa M, Heikkinen S, Rissanen A, Laakso M. Polymorphism of the beta-3-adrenergic receptor gene affects basal metabolic rate in obese Finns. Diabetes 1997;46:77-80.
11. Shihara N, Yasuda K, Moritani T, Ue H, Adachi T, Tanaka H, Tsuda K, Seino Y. The association between Trp64Arg polymorphism of the beta-3-adrenergic receptor and autonomie nervous system activity. J Clin Endocrinol Metab 1999;84:1623-1627.
12. Mitchell B, Blangero J, Comuzzie A, Almasy L, Shuldiner A, Silver K, Stern M, MacCluer J, Hixson J. A paired sibling analysis of the beta-3 adrenergic receptor and obesity in Mexican Americans. J Clin Invest 1998;101:584-587.
13. Gagnon J, Mauriege P, Roy S, Sjostrom D, Chagnon YC, Dionne FT, Oppert JM, Perusse L, Sjostrom L, Bouchard C. The Trp64Arg mutation of the beta3 adrenergic receptor gene has no effect on obesity phenotypes in the Quebec Family Study and Swedish Obese Subjects cohorts. J Clin Invest 1996;98:2086-2093.
14. Fujisawa T, Ikegami H, Kawaguchi Y, Ogihara T. Meta-analysis of the association of the Trp64Arg polyomorphism of the beta-3-adrenergic receptor gene with body mass index. J Clin Endocrinol Metab 1998;83:2441-2444.
15. Silver K, Walston J, Wang Y, Dowse G, Zimmet P, Shuldiner AR. Molecular scanning for mutations in the beta 3-adrenergic receptor gene in Nauruans with obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:4155-4158.
16. Silver K, Mitchell BD, Walston J, Sorkin JD, Stern MP, Roth J, Shuldiner AR. TRP64ARG beta 3-adrenergic receptor and obesity in Mexican Americans. Hum Genet 1997;101:306-311.
17. Elisabeth Widen, Markku Lehto, Timo Kanninen, Jeremy Walston, Alan R. Shuldiner and Leif Groop. Association of a Polymorphism in the beta3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. The New England Journal of Medicine 1995;10:348-351.
18. Nagase T, Aoki A, Yamamoto M, Yasuda H, Kado S, Nishikawa M, Kugai N, Akatsu T, Nagata N. Lack of association between the Trp64 Arg mutation in the beta 3-adrenergic receptor gene and obesity in Japanese men: A longitudinal analysis. J Clin Endocrinol Metab 1997;82:1284-1287.
19. Rissanen J, Kuopusjarvi J, Pihlajamaki J, Sipilainen R, Heikkinen S, Vanhala M, Kekalainen P, Kuusisto J, Laakso M. The Trp64Arg polymorphism of the beta 3-Adrenergic receptor gene. Lack of association with NIDDM and features of insulin resistance syndrome. Diabetes Care 1997;20:1319-1323.
20. Oeveren van-Dybicz AM, Vonkeman HE, Bon MA, van den Bergh FA, Vermes I. Beta 3-adrenergic receptor gene polymorphism and type 2 diabetes in a Caucasian Population. Diabetes Obes Metab 2001;3:47-51.
21. Kim-Motoyama H, Yasuda K, Yamaguchi T, Yamada N, Katakura T, Shuldiner AR, Akanuma Y, Ohashi Y, Yazaki Y, Kadowaki T. A mutation of the beta 3-adrenergic receptor is associated with visceral obesity but decreased serum triglyceride. Diabetologia 1997;40:469-472.
22. Fujisawa T, Ikegami H, Yamato E, Takekawa K, Nakagawa Y, Hamada Y, Oga T, Ueda H, Shintani M, Fukuda M, Ogihara T. Association of Trp64Arg mutation of the beta3-adrenergic-receptor with NIDDM and body weight gain. Diabetologia 1996;39:349-352.
23. Vendrell J, Gutierrez C, Broch M, Fernandez-Real JM, Aguilar C, Richart C. Beta 3-adrenoreceptor gene polymorphism and leptin. Lack of relationship in type 2 diabetic patients. Clin Endocrinol 1998;49:679-683.
24. Ueda K, Tanizawa Y, Oota Y, Inoue H, Kizuki N, Inoue H, Tsukuda K, Asano T, Oka Y. Prevalence of the Trp64Arg missense mutation of the beta3-adrenergic receptor gene in Japanese subjects. Metabolism 1997;46:199-202.
25. Awata T, Katayama S. Genetic variation in the beta3-adrenergic receptor in Japanese NIDDM patients. Diabetes Care 1996;19:271-272.
26. Kadowaki H, Yasuda K, Iwamoto K, Otabe S, Shimokawa K, Silver K, Walston J, Yoshinaga H, Kosaka K, Yamada N, Saito Y, Hagura R, Akanuma Y, Shuldiner A, Yazaki Y and Kadowaki T. A mutation in the beta 3-adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects. Biochem Biophys Res Commun 1995;215:555-560.
27. Carlsson M, Orho-Melander M, Hedenbro J, Groop LC. Common variants in the beta2-(Gln27Glu) and beta3-(Trp64Arg) - Adrenoceptor genes are associated with elevated serum NEFA concentrations and type II diabetes. Diabetologia 2001;44:629-636.
28. Yoshioka K, Yoshida T, Sakane N, Umekawa T, Takahashi T, Sakai Y, Kondo M. Association of Trp64Arg mutation of the beta 3-adrenergic receptor gene with NIDDM, current and maximal body mass index. Diabetologia 1996;39:1410-1411.
29. Janssen JA, Koper JW, Stolk RP, Englaro P, Uitterlinden AG, Huang Q, van Leeuwen JP, Blum WF, Attanasio AM, Pols HA, Grobbee DE, de long FH, Lamberts SW. Lack of associations between serum leptin, a polymorphism in the gene for the beta 3-adrenergic receptor and glucose tolerance in the Dutch population. Clin Endocrinol 1998;49:229-234.
30. Hegele RA, Harris SB, Hanley AJ, Azouz H, Connelly PW, Zinman B. Absence of association between genetic variation of the beta 3-adrenergic receptor and metabolic phenotypes in Oji-Cree. Diabetes Care 1998;21:851-854.
31. Azuma N, Yoshimasa Y, Nishimura H, Yamamoto Y, Masuzaki H, Suga J, Shigemoto M, Matsuoka N, Tanaka T, Satoh N, Igaki T, Miyamoto Y, Itoh H, Yoshimasa T, Hosoda K, Nishi S, Nakao K. The significance of the Trp 64 Arg mutation of the beta3-adrenergic receptor gene in impaired glucose tolerance, non-insulin-dependent diabetes mellitus, and insulin resistance in Japanese subjects. Metabolism 1998;47:456-460.
32. Sakane N, Yoshida T, Yoshioka K, Umekawa T, Takakura Y, Kogure A, Kondo M. Genetic variation in the beta 3-adrenergic receptor in Japanese NIDDM patients. Diabetes Care 1996;19:1034-1035.
33. Evans D, Minouchehr S, Hagemann G, Mann WA, Wendt D, Wolf A, Beisiegel U. Frequency of and interaction between polymorphisms in the beta3-adrenergic receptor and in uncoupling proteins 1 and 2 and obesity in Germans. Int J Obes Relat Metab Disord 2000;24:1239-1245.
34. Yuan X, Yamada K, Koyama K, Ichikawa F, Ishiyama S, Koyanagi A, Koyama W, Nonaka K. Beta 3-adrenergic receptor gene polymorphism is not a major genetic determinant of obesity and diabetes in Japanese general population. Diabetes Res Clin Pract 1997;37:1-7.
35. Oizumi T, Daimon M, Saitoh T, Kameda W, Yamaguchi H, Ohnuma H, Igarashi M, Eguchi H, Manaka H, Tominaga M, Kato T. Genotype Arg/Arg, but not Trp/Arg, of the Trp64Arg polymorphism of the beta(3)-adrenergic receptor is associated with type 2 diabetes and obesity in a large Japanese sample. Diabetes Care 2001;24:1579-1583.
36. Ghosh S, Langefeld CD, Ally D, Watanabe RM, Hauser ER, Magnuson VL, Nylund SJ, Valle T, Eriksson J, Bergman RN, Tuomilehto J, Collins FS, Boehnke M. The W64R variant of the beta3-adrenergic receptor is not associated with type II diabetes or obesity in a large Finnish sample. Diabetologia 1999;42:238-244.
37. Li LS, Lonnqvist F, Luthman H, Arner P. Phenotypic characterization of the Trp64Arg polymorphism in the beta 3-adrenergic receptor gene in normal weight and obese subjects. Diabetologia 1996;39:857-860.
38. Biery AJ, Ebbesson SO, Shuldiner AR, Boyer BB. The beta(3)-adrenergic receptor TRP64ARG polymorphism and obesity in Alaskan Eskimos. Int J Obes Relat Metab Disord 1997;21:1176-1179.
39. Yoshida T, Sakane N, Umekawa T, Sakai M, Takahashi T, Kondo M. Mutation of beta 3-adrenergic-receptor gene and response to treatment of obesity. Lancet 1995;346:1433-1434.
40. Proenza AM, Poissonnet CM, Ozata M, Ozen S, Guran S, Palou A, Strosberg AD. Association of sets of alleles of genes encoding beta3-adrenoreceptor, uncoupling protein 1 and lipoprotein lipase with increased risk of metabolic complications in obesity. Int J Obes Relat Metab Disord 2000;24:93-100.
41. Corbalan MS, Marti A, Forga L, Martinez-Gonzalez MA, Martinez JA. The risk of obesity and the Trp64Arg polymorphism of the beta(3)-adrenergic receptor: Effect modification by age. Ann Nutr Metab 2002;46:152-158.
42. Hinney A, Lentes KU, Rosenkranz K, Barth N, Roth H, Ziegler A, Hennighausen K, Coners H, Wurmser H, Jacob K, Romer G, Winnikes U, Mayer H, Herzog W, Lehmkuhl G, Poustka F, Schmidt MH, Blum WF, Pirke KM, Schafer H, Grzeschik KH, Remschmidt H, Hebebrand J. Beta 3-adrenergic-receptor allele distributions in children, adolescents and young adults with obesity, underweight or anorexia nervosa. Int J Obes Relat Metab Disord 1997;21:224-230.
43. Sakane N, Yoshida T, Umekawa T, Kondo M, Sakai Y, Takahashi T. Beta 3-adrenergic-receptor polymorphism: A genetic marker for visceral fat obesity and the insulin resistance syndrome. Diabetologia 1997;40:200-204.
44. Kawamura T, Egusa G, Fujikawa R, Okubo M. Beta(3)-adrenergic receptor gene variant is associated with upper body obesity only in obese Japanese-American men but not in women. Diabetes Res Clin Pract 2001;54:49-55.
45. Thomas GN, Tomlinson B, Chan JC, Young RP, Critchley JA. The Trp64Arg polymorphism of the beta3-adrenergic receptor gene and obesity in Chinese subjects with components of the metabolic syndrome. Int J Obes Relat Metab Disord 2000;24:545-551.
46. Endo K, Yanagi H, Hirano C, Hamaguchi H, Tsuchiya S, Tomura S. Association of Trp64Arg polymorphism of the beta3-adrenergic receptor gene and no association of Gln223Arg polymorphism of the leptin receptor gene in Japanese schoolchildren with obesity. Int J Obes Relat Metab Disord 2000;24:443-449.
47. Ishii T, Hirose H, Kawai T, Hayashi K, Maruyama H, Saito I, Saruta T. Effects of intestinal fatty acid-binding protein gene Ala54Thr polymorphism and beta3-adrenergic receptor gene Trp64Arg polymorphism on insulin resistance and fasting plasma glucose in young to older Japanese men. Metabolism 2001;50:1301-1307.
48. Walston J, Silver K, Hilfiker H, Andersen RE, Seibert M, Beamer B, Roth J, Poehlman E, Shuldiner AR. Insulin response to glucose is lower in individuals homozygous for the Arg 64 variant of the beta-3-adrenergic receptor. J Clin Endocrinol Metab 2000;85:4019-4022.
49. Sakane N, Yoshida T, Umekawa T, Kogure A, Takakura Y, Kondo M. Effects of Trp64Arg mutation in the beta 3-adrenergic receptor gene on weight loss, body fat distribution, glycemic control, and insulin resistance in obese type 2 diabetic patients. Diabetes Care 1997;20:1887-1890.
50. Buettner R, Schaffler A, Arndt H, Rogler G, Nusser J, Zietz B, Enger I, Hugl S, Cuk A, Scholmerich J, Palitzsch KD. The Trp64Arg polymorphism of the beta 3-adrenergic receptor gene is not associated with obesity or type 2 diabetes mellitus in a large population-based Caucasian cohort. J Clin Endocrinol Metab 1998;83:2892-2897.
51. Urhammer SA, Hansen T, Borch-Johnsen K, Pedersen O. Studies of the synergistic effect of the Trp/Arg64 polymorphism of the beta3-adrenergic receptor gene and the -3826 A->G variant of the uncoupling protein-1 gene on features of obesity and insulin resistance in a population-based sample of 379 young Danish subjects. J Clin Endocrinol Metab 2000;85:3151-3154.
52. Urhammer SA, Clausen JO, Hansen T, Pedersen O. Insulin sensitivity and body weight changes in young white carriers of the codon 64 amino acid polymorphism of the beta 3-adrenergic receptor gene. Diabetes 1996;45:1115-1120.
53. Fujisawa T, Ikegami H, Yamato E, Hamada Y, Kamide K, Rakugi H, Higaki J, Murakami H, Shimamoto K, Ogihara T. Trp64Arg mutation of beta3-adrenergic receptor in essential hypertension: Insulin resistance and the adrenergic system. Am J Hypertens 1997;10:101-105.
54. Pihlajamaki J, Rissanen J, Valve R, Heikkinen S, Karjalainen L, Laakso M. Different regulation of free fatty acid levels and glucose oxidation by the Trp64Arg polymorphism of the beta3-adrenergic receptor gene and the promoter variant (A-3826G) of the uncoupling protein 1 gene in familial combined hyperlipidemia. Metabolism 1998;47:1397-1402.
55. Sheu WH, Lee WJ, Yao YE, Jeng CY, Young MM, Chen YT. Lack of association between genetic variation in the beta3-adrenergic receptor gene and insulin resistance in patients with coronary heart disease. Metabolism 1999;48:651-654.
56. Christiansen C, Poulsen P, Beck-Nielsen H. The Trp64Arg mutation of the adrenergic beta-3 receptor gene impairs insulin secretion: A twin study. Diabet Med 1999;16:835-840.
57. Alevizaki M, Thalassinou L, Grigorakis SI, Philippou G, Lili K, Souvatzoglou A, Anastasiou E. Study of the Trp64Arg polymorphism of the beta3-adrenergic receptor in Greek women with gestational diabetes. Diabetes Care 2000;23:1079-1083.
58. Festa A, Krugluger W, Shnawa N, Hopmeier P, Haffner SM, Schernthaner G. Trp64Arg polymorphism of the beta3-adrenergic receptor gene in pregnancy: Association with mild gestational diabetes mellitus. J Clin Endocrinol Metab 1999;84:1695-1699.
59. Kim SH, Kim DJ, Seo IA, Min YK, Lee MS, Kim KW, Lee MK. Significance of beta2-adrenergic receptor gene polymorphism in obesity and type 2 diabetes mellitus in Korean subjects. Metabolism 2002;51:833-837.
60. Chang TJ, Tsai MH, Jiang YD, Lee B, Lee KC, Lin JY, Chiu KC, Tai TY, Chuang LM. The Arg 16Gly polymorphism of human beta2-adrenoreceptor is associated with type 2 diabetes in Taiwanese people. Clin Endocrinol 2002;57:685-690.
61. Ishiyama-Shigemoto S, Yamada K, Yuan X, Ichikawa F, Nonaka K. Association of polymorphisms in the beta2-adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus. Diabetologia 1999;42:98-101.
62. Bengtsson K, Orho-Melander M, Melander O, Lindblad U, Ranstam J, Rastam L, Groop L. Beta(2)-adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes. Hypertension 2001;37:1303-1308.
63. Kawamura T, Egusa G, Fujikawa R, Okubo M. Gln27Glu variant of the beta2-adrenergic receptor gene is not associated with obesity and diabetes in Japanese-Americans. Metabolism 2001;50:443-446.
64. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta-1-adrenergic receptor. J Biol Chem 1999;274:12670-12674.
65. Bengtsson K, Melander O, Orho-Melander M, Lindblad U, Ranstam J, Rastam L, Groop L. Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation 2001;104:187-190.
66. Large V, Reynisdottir S, Langin D, Fredby D, Klannemark M, Holm C, Arner P. Decreased expression and function of adipocyte hormone-sensitive lipase in subcutaneous fat cells of obese subjects. J Lipid Res 1999;40:2059-2065.
67. Talmud PJ, Palmen J, Walker M. Identification of genetic variation in the human hormone-sensitive lipase gene and 5″ sequences: Homology of 5″ sequences with mouse promoter and identification of potential regulatory elements. Biochem Biophys Res Commun, 1998;252:661-668.
68. Klannemark M, Orho M, Langin D, Laurell H, Holm C, Reynisdottir S, Arner P, Groop L. The putative role of the hormone-sensitive lipase gene in the pathogenesis of type II diabetes mellitus and abdominal obesity. Diabetologia 1998;41:1516-1522.
69. Shimada F, Makino H, Hashimoto N, Iwaoka H, Taira M, Nozaki O, Kanatsuka A, Holm C, Langin D, Saito Y. Detection of an amino acid polymorphism in hormone-sensitive lipase in Japanese subjects. Metabolism 1996;45:862.
70. Hotamisligil G, Shargill N, Spiegelman B. Adipose expression of tumor necrosis factor-a: Direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
71. Hotamisigil G, Arner P, Caro J, Atkinson R, Spiegelman B. Increased adipose tissue expression of tumor necrosis factor-a in human obesity and insulin resistance. J Clin Invest 1995;95:2409-2415.
72. Kellerer M, Rett K, Renn W, Groop L, Häring H. Circulating TNF-alpha and leptin levels in offspring of NIDDM patients do not correlate to individual insulin sensitivity. Horm Metab Res 1996;28:737-743.
73. Furuta M, Yano Y, Ito K, Gabazza EC, Katsuki A, Tanaka T, Ohtake K, Hirata N, Hori Y, Araki-Sasaki R, Sumida Y, Adachi Y. Relationship of the tumor necrosis factor-alpha-308 A/G promoter polymorphism with insulin sensitivity and abdominal fat distribution in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2002;56:141-145.
74. Heijmans BT, Westendotp RG, Droog S, Kluft C, Knook DL, Slagboom PE. Association of the tumour necrosis factor alpha -308G/A polymorphism with the risk of diabetes in an elderly population-based cohort. Genes Immun 2002;3:225-228.
75. Lee SC, Pu YB, Thomas GN, Lee ZS, Tomlinson B, Cockram CS, Critchley JA, Chan JC. Tumor necrosis factor alpha gene G-308A polymorphism in the metabolic syndrome. Metabolism 2000;49:1021-1024.
76. Shiau MY, Wu CY, Huang CN, Hu SW, Lin SJ, Chang YH. TNF-alpha polymorphisms and type 2 diabetes mellitus in Taiwanese patients. Tissue Antigens 2003;61:393-397.
77. Ko GT, Lee SC, Pu YB, Ng MC, So WY, Thomas N, Chan WB, Cockram CS, Chan JC. Tumour necrosis factor-alpha promoter gene polymorphism at - 308 (genotype AA) in Chinese subjects with Type 2 diabetes. Diabet Med 2003;20:167-168.
78. Li H, Groop L, Nilsson A, Weng J, Tuomi T. A combination of human leukocyte antigen DQB1*02 and the tumor necrosis factor alpha promoter G308A polymorphism predisposes to an insulin-deficient phenotype in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2767-2774.
79. Kamizono S, Yamada K, Seki N, Higuchi T, Kimura A, Nonaka K, Itoh K. Susceptible locus for obese type 2 diabetes mellitus in the 5′-flanking region of the tumor necrosis factor-alpha gene. Tissue Antigens 2000;55:449-152.
80. Fernandéz-Real J, Gutierrez C, Ricart W, Casamitjana R, Fernandéz-Castanér M, Vendrell J, Richart C, Soler J. The TNF-alpha gene Nco I polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels. Diabetes 1997;46:1468-1472.
81. Walston J, Seibert M, Jen-Yen C, Cheskin L, Andersen R. Tumor necrosis factor-alpha-238 and-308 polymorphisms do not associate with traits related to obesity and insulin resistance. Diabetes 1999;48:2096-2098.
82. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
83. Auwerx J. PPARgamma, the ultimate thriphty gene. Diabetologia 1999;42:1033-1049.
84. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn C. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. New Engl J Med 1998;339:953-959.
85. Nemoto M, Sasaki T, Deeb SS, Fujimoto WY, Tajima N. Differential effect of PPARgamma2 variants in the development of type 2 diabetes between native Japanese and Japanese Americans. Diabetes Res Clin Pract 2002;57:131-137.
86. Oh EY, Min KM, Chung JH, Min YK, Lee MS, Kim KW, Lee MK. Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. J Clin Endocrinol Metab 2000;85:1801-1804.
87. Niskanen L, Lindi V, Erkkila A, Sivenius K, Luoma J, Yla-Herttuala S, Laakso M, Uusitupa MI. Association of the PRO12ALA polymorphism of the PPAR-gamma2 gene with oxidized low-density lipoprotein and cardiolipin autoantibodies in nondiabetic and type 2 diabetic subjects. Metabolism 2003;52:231-237.
88. Simon I, Vendrell J, Gutierrez C, Fernandez-Real JM, Vendrell I, Gallart L, Fontova R, Richart C. Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma is associated with increased leptin levels in women with type-2 diabetes mellitus. Horm Res 2002;58:143-149.
89. Hegele RA, Cao H, Harris SB, Zinman B, Hanley AJ, Anderson CM. Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 2000;85:2014-2019.
90. Hasstedt SJ, Ren QF, Teng K, Elbein SC. Effect of the peroxisome proliferator-activated receptor-gamma 2 pro(12)ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. J Clin Endocrinol Metab 2001;86:536-541.
91. Lei HH, Chen MH, Yang WS, Chiu MC, Chen MC, Tai TY, Chuang LM. Peroxisome proliferator-activated receptor gamma 2 Pro12Ala gene variant is strongly associated with larger body mass in the Taiwanese. Metabolism 2000;49:1267-1270.
92. Evans D, de Heer J, Hagemann C, Wendt D, Wolf A, Beisiegel U, Mann WA. Association between the P12A and c1431t polymorphisms in the peroxisome proliferator activated receptor gamma (PPAR gamma) gene and type 2 diabetes. Exp Clin Endocrinol Diabetes 2001;109:151-154.
93. Clement K, Hercberg S, Passinge B, Galan P, Varroud-Vial M, Shuldiner AR, Beamer BA, Charpentier G, Guy-Grand B, Froguel P, Vaisse C. The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord 2000;24:391-393.
94. Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus. Biochem Biophys Res Commun 1999;254:450-453.
95. Ek J, Andersen G, Urhammer SA, Hansen L, Carstensen B, Borch-Johnsen K, Drivsholm T, Berglund L, Hansen T, Lithell H, Pedersen O. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 2001;44:1170-1176.
96. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, Mohlke KL, Valle TT, Ehnholm C, Buchanan TA, Bergman RN, Collins FS, Boehnke M, Tuomilehto J. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala variant: Association with type 2 diabetes and trait differences. Diabetes 2001;50:886-890.
97. Ardlie KG, Lunetta KL, Seielstad M. Testing for population sub-division and association in four case-control studies. Am J Hum Genet 2002;71:304-311.
98. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000;271:212-216.
99. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb SS, Amouyel P. Impact of the Peroxisome Proliferator Activated Receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000;24:195-199.
100. Barroso I, Luan J, Middelberg RP, Harding AH, Franks PW, Jakes RW, Clayton D, Schafer AJ, O'Rahilly S, Wareham NJ. Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action. PLoS Biol 2003;1:E20.
101. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N, Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E, Kasuga M. The Pro12 -> Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: Possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001;50:891-894.
102. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics 1998;20:284-287.
103. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998;92:829-839.
104. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999;98:115-124.
105. Ek J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, Hansen T, Pedersen O. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia 2001;44:2220-2226.
106. Lacquemant C, Chikri M, Boutin P, Samson C, Froguel P. No association between the G482S polymorphism of the proliferator-activated receptor- gamma coactivator-1 (PGC-1) gene and Type II diabetes in French Caucasias. Diabetologia 2002;45:602-603.
107. Andersen G, Hansen T, Gharani N, Frayling TM, Owen KR, Sampson M, Ellard S, Walker M, Hitman GA, Hattersley AT, McCarthy MI, Pedersen O. A common Gly482Ser polymorphism of PGC-1 is associated with type 2 diabetes mellitus in two European populations (Abstract). Diabetes 2002;51:A49.
108. Herzig S, Hedrick S, Morantte I, Koo SH, Galimi F, Montminy M. CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma. Nature 2003;426:190-193.
109. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov IP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003;34:267-273.
110. Patti ME, Butte AI, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EI, Goldfine AB, Mun E, DeFronzo R, Finlayson I, Kahn CR, Mandarino LJ. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci 2003;100:8466-8471.
111. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-26749.
112. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
113. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-343.
114. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody I, Wu M, Ventre I, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174.
115. Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002;277:25226-25232.
116. Arita Y, Kihara S, Ouchi N, Takahaschi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;275:79-83.
117. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360:57-58.
118. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tmoita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946.
119. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-ecreted protein Arp30 enhances hepatic insulin action. Nat Med 2001;7:947-953.
120. Stumvoll M, Tschritter O, Fritsche A, Staiger H, Renn H, Weisser M, Machicao F, Häring H. Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity. Diabetes 2002;51:37-41.
121. Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, Yamauchi T, Otabe S, Okada T, Eto K, Kadowaki H, Hagura R, Akanuma Y, Yazaki Y, Nagai R, Taniyama M, Matsubara K, Yoda M, Nakano Y, Tomita M, Kimura S, Ito C, Froguel P, Kadowaki T. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002;51:536-540.
122. Menzaghi C, Ercolino T, Di Paola R, Berg AH, Warram JH, Scherer PE, Trischitta V, Doria A. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 2002;51:2306-2312.
123. Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S, Boutin P, Vaxillaire M, Lepretre F, Dupont S, Hara K, Clement K, Bihain B, Kadowaki T, Froguel P. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 2002;11:2607-2614.
124. Vionnet N, Hani El-H, Dupont S, Gallina S, Francke S, Dotte S, De Matos F, Durand E, Leprêtre F, Lecoeur C, Gallina P, Zekiri L, Dina, Froguel P. Genome wide search for type 2 diabetes-susceptibility genes in French whites: Evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000;67:1470-1480.
125. Cederberg A, Grönning LM, Ahrén B, Taskén K, Carlsson P, Enerbäck S. FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resistance. Cell 2001;106:563-573.
126. Ridderstråle M, Carlsson E, Klannemark M, Cederberg M, Kösters C, Tomqvist H, Storgaard H, Vaag A, Enerbäck S, Groop L. FOXC2 mRNA and a 5′UTR polymorphism of the gene are associated with insulin resistance. Diabetes 2002;51:3554-3560.
127. Osawa H, Onuma H, Murakami A, Ochi M, Nishimiya T, Kato K, Shimizu I, Fujii Y, Ohashi J, Makino H. Systematic search for single nucleotide polymorphisms in the FOXC2 gene: The absence of evidence for the association of three frequent single nucleotide polymorphisms and four common haplotypes with Japanese type 2 diabetes. Diabetes 2003;52:562-567.
128. Yanagisawa K, Hingstrup Larsen L, Andersen G, Drivsholm T, Cederberg A, Westergren R, Borch-Johnsen K, Pedersen O, Enerback S, Hansen T. The FOXC2 -512C>T variant is associated with hypertriglyceridaemia and increased serum C-peptide in Danish Caucasian glucose-tolerant subjects. Diabetologia 2003;46:1576-1580.
129. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312.
130. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001;285:561-564.
131. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-a action in humans. Diabetes 2001;50:2199-2202.
132. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Resistin gene expression in human adipocytes is not related to insulin resistance. Obesity Research 2002;10:1-5.
133. Sentinelli F, Romeo S, Area M, Filippi E, Leonetti F, Banchieri M, Di Mario U, Baroni MG. Human resistin gene, obesity, and type 2 diabetes. Diabetes 2002;51:860-862.
134. Osawa H, Onuma H, Murakami A, Ochi M, Nishimiya T, Kato K, Shimizu I, Fujii Y, Ohashi J, Makino H. Systematic search for single nucleotide polymorphisms in the resistin gene: The absence of evidence for the association of three identified single nucleotide polymorphisms with Japanese type 2 diabetes. Diabetes 2002;51:863-866.
135. Engert JC, Vohl M-C, Williams SM, Lepage P, Loredo-Osti JC, Faith J, Doré C, Renaud Y, Burtt NP, Villeneuve A, Hirschhorn JN, Altshuler D, Groop LC, Després J-P, Gaudet D, Hudson TJ. 5′ flanking variants of resistin are associated with obesity. Diabetes 2002;51:1629-1634.
136. Wang H, Chu WS, Hemphill C, Elbein SC. Human resistin gene: Molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab 2002;87:2520-2524.
137. Pizzuti A, Argiolas A, Di Paola R, Baratta R, Rauseo A, Bozzali M, Vigneri R, Dallapiccola B, Trischitta V, Frittitta L. An ATG repeat in the 3′-untranslated region of the human resistin gene is associated with a decreased risk of insulin resistance. J Clin Endocrinol Metab 2002;87:4403-4406.
138. Smith SR, Bai F, Charbonneau C, Janderova L, Argyropoulos G. A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes 2003;52:1611-1618.
139. Ma X, Warram JH, Trischitta V, Doria A. Genetic variants at the resistin locus and risk of type 2 diabetes in Caucasians. J Clin Endocrinol Metab 2002;87:4407-4410.
140. Hanis C, Boerwinkle E, Chakraborty R, Ellsworth D, Concannon P, Stirling B, Morrison V, Wapelhorst B, Spielman R, Goglin-Ewens K, Shephard J, Williams S, Risch N, Hinds D, Iwasaki N, Ogata M, Omori Y, Petzold C, Rietsch H, Schröder H-E, Schulze J, Cox N, Menzel S, Boriraj V, Chen X, Lim L, Lindner T, Mereu L, Wang Y-Q, Xiang K, Yamagata K, Yang Y, Bell G. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet 1996;13.
141. Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M, Hinokio Y, Lindner TH, Mashima H, Schwarz PE, del Bosque-Plata L, Horikawa Y, Oda Y, Yoshiuchi I, Colilla S, Polonsky KS, Wei S, Concannon P, Iwasaki N, Schulze J, Baier LJ, Bogardus C, Groop L, Boerwinkle E, Hanis CL, Bell GI. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000;26:163-175.
142. Daimon M, Oizumi T, Saitoh T, Kameda W, Yamaguchi H, Ohnuma H, Igarashi M, Manaka H, Kato T. Calpain 10 gene polymorphisms are related, not to type 2 diabetes, but to increased serum cholesterol in Japanese. Diabetes Res Clin Pract 2002;56:147-152.
143. Tsar HJ, Sun G, Weeks DE, Kaushal R, Wolujewicz M, McGarvey ST, Tufa J, Viali S, Deka R. Type 2 diabetes and three calpain-10 gene polymorphisms in Samoans: No evidence of association. Am J Hum Genet 2001;69:1236-1244.
144. Orho-Melander M, Klannemark M, Svensson M, Ridderstråle M, Lindgren C, Groop L. Variants in the calpain-10 gene predispose to insulin resistance and elevated free fatty acid levels. Diabetes 2002;51:2658-2664.
145. Horikawa Y, Oda N, Yu L, Imamura S, Fujiwara K, Makino M, Seino Y, Itoh M, Takeda J. Genetic variations in calpain-10 gene are not a major factor in the occurrence of type 2 diabetes in Japanese. J Clin Endocrinol Metab 2003;88:244-247.
146. Malecki MT, Moczulski DK, Klupa T, Wanic K, Cyganek K, Frey J, Sieradzki J. Homozygous combination of calpain 10 gene haplotypes is associated with type 2 diabetes mellitus in a Polish population. Eur J Endocrinol 2002;146:695-699.
147. Evans JC, Frayling TM, Cassell PG, Saker PJ, Hitman GA, Walker M, Levy JC, O'Rahilly S, Rao PV, Bennett AJ, Jones EC, Menzel S, Prestwich P, Simecek N, Wishart M, Dhillon R, Fletcher C, Millward A, Demaine A, Wilkin T, Horikawa Y, Cox NJ, Bell GI, Ellard S, McCarthy MI, Hattersley AT. Studies of association between the gene for calpain-10 and type 2 diabetes mellitus in the United Kingdom. Am J Hum Genet 2001;69:544-552.
148. Rasmussen SK, Urhammer SA, Berglund L, Jensen JN, Hansen L, Echwald SM, Borch-Johnsen K, Horikawa Y, Mashima H, Lithell H, Cox NJ, Hansen T, Bell GI, Pedersen O. Variants within the calpain-10 gene on chromosome 2q37 (NIDDM1) and relationships to type 2 diabetes, insulin resistance, and impaired acute insulin secretion among Scandinavian Caucasians. Diabetes 2002;51:3561-3567.
149. Fingerlin TE, Erdos MR, Watanabe RM, Wiles KR, Stringham HM, Mohlke KL, Silander K, Valle TT, Buchanan TA, Tuomilehto J, Bergman RN, Boehnke M, Collins FS. Variation in three single nucleotide polymorphisms in the calpain-10 gene not associated with type 2 diabetes in a large Finnish cohort. Diabetes 2002;51:1644-1648.
150. Garant MJ, Kao WH, Brancati F, Coresh J, Rami TM, Hanis CL, Boerwinkle E, Shuldiner AR. SNP43 of CAPN10 and the risk of type 2 Diabetes in African-Americans: The Atherosclerosis Risk in Communities Study. Diabetes 2002;51:231-237.
151. Baier LJ, Permana PA, Yang X, Pratley RE, Hanson RL, Shen GQ, Mott D, Knowler WC, Cox NJ, Horikawa Y, Oda N, Bell GI, Bogardus C. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest 2000;106:R69-R73.
152. Sreenan SK, Zhou Y-P, Otani K, Hansen PA, Currie KPM, Pan C-Y, Lee J-P, Ostrega DM, Pugh W, Horikawa Y, Cox NJ, Hanis CL, Burant CF, Fox AP, Bell GI, Polonsky KS. Calpains play a role in insulin secretion and action. Diabetes 2001;50:2013-2020.
153. Weedon MN, Schwarz PE, Horikawa Y, Iwasaki N, Illig T, Holle R, Rathmann W, Selisko T, Schulze J, Owen KR, Evans J, Del Bosque-Plata L, Hitman G, Walker M, Levy JC, Sampson M, Bell GI, McCarthy MI, Hattersley AT, Frayling TM. Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. Am J Hum Genet 2003;73:1208-1212.
154. Wang Y, Xiang K, Zheng T, Jia W, Shen K, Li J. The UCSNP44 variation of calpain 10 gene on NIDDM1 locus and its impact on plasma glucose levels in type 2 diabetic patients. Zhonghua Yi Xue Za Zhi 2002;82:613-616.
155. Cassell PG, Jackson AE, North BV, Evans JC, Syndercombe-Court D, Phillips C, Ramachandran A, Snehalatha C, Gelding SV, Vijayaravaghan S, Curtis D, Hitman GA. Haplotype combinations of calpain 10 gene polymorphisms associate with increased risk of impaired glucose tolerance and type 2 diabetes in South Indians. Diabetes 2002;51:1622-1628.
156. Maddux B, Sbraccia P, Kumakura S, Sasson S, Youngren J, Fisher A, Spemcer S, Grupe A, Henzel W, Stewart T, Reaven G, Goldfine I. Membrane glycoprotein PC-1 and insulin resistance in non-insulin dependent diabetes mellitus. Nature 1995;273:448-451.
157. Pizzuti A, Frittitta L, Argiolas A, Baratta R, Goldfine ID, Bozzali M, Ercolino T, Scarlato G, lacoviello L, Vigneri R, Tassi V, Trischitta V. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes 1999;48:1881-1884.
158. Gu HF, Almgren P, Lindholm E, Frittitta L, Pizzuti A, Trischitta V, Groop LC. Association between the human glycoprotein PC-1 gene and elevated glucose and insulin levels in a paired-sibling analysis. Diabetes 2000;49:1601-1603.
159. Rasmussen SK, Urhammer SA, Pizzuti A, Echwald SM, Ekstrom CT, Hansen L, Hansen T, Borch-Johnsen K, Frittitta L, Trischitta V, Pedersen O. The K121Q variant of the human PC-1 gene is not associated with insulin resistance or type 2 diabetes among Danish Caucasians. Diabetes 2000;49:1608-1611.
160. Kubaszek A, Pihlajamaki J, Karhapaa P, Vauhkonen I, Laakso M. The K121Q polymorphism of the PC-1 gene is associated with insulin resistance but not with dyslipidemia. Diabetes Care 2003;26:464-467.
161. Sun X, Rothenberg P, Kahn R, Backer J, Arakai E, Wilden P, Cahill D, Goldhill B, White M. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991;352:73-77.
162. Almind K, Bjorbaek C, Vestergaard H, Hansen T, Echwald S, Pedersen O. Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet 1993;342:828-832.
163. Panz VR, Raal FJ, O'Rahilly S, Kedda MA, Joffe BI. Insulin receptor substrate-1 gene variants in lipoatrophic diabetes mellitus and non-insulin-dependent diabetes mellitus: A study of South African black and white subjects. Hum Genet 1997;101:118-119.
164. Celi FS, Negri C, Tanner K, Raben N, De Pablo F, Rovira A, Pallardo LF, Martin-Vaquera P, Stern MP, Mitchell BD, Shuldiner AR. Molecular scanning for mutations in the insulin receptor substrate-1 (IRS-1) gene in Mexican Americans with Type 2 diabetes mellitus. Diabetes Metab Res Rev 2000;16:370-377.
165. Celi FS, Silver K, Walston J, Knowler WC, Bogardus C, Shuldiner AR. Lack of IRS-1 codon 513 and 972 polymorphism in Pima Indians. J Clin Endocrinol Metab 1995;80:2827-2879.
166. Imai Y, Fusco A, Suzuki Y, Lesniak MA, D'Alfonso R, Sesti G, Bertoli A, Lauro R, Accili D, Taylor SI. Variant sequences of insulin receptor substrate-1 in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1994;79:1655-1658.
167. Hitman GA, Hawrami K, McCarthy MI, Viswanathan M, Snehalatha C, Ramachandran A, Tuomilehto J, Tuomilehto-Wolf E, Nissinen A, Pedersen O. Insulin receptor substrate-1 gene mutations in NIDDM; implications for the study of polygenic disease. Diabetologia 1995;38:481-186.
168. Lepretre F, Vionnet N, Budhan S, Dina C, Powell KL, Genin E, Das AK, Nallam V, Passa P, Froguel P. Genetic studies of polymorphisms in ten non-insulin-dependent diabetes mellitus candidate genes in Tamil Indians from Pondichery. Diabetes Metab 1998;24:244-250.
169. Ura S, Araki E, Kishikawa H, Shirotani T, Todaka M, Isami S, Shimoda S, Yoshimura R, Matsuda K, Motoyoshi S, Miyamura N, Kahn CR, Shichiri M. Molecular scanning of the insulin receptor substrate-1 (1RS-1) gene in Japanese patients with NIDDM: Identification of five novel polymorphisms. Diabetologia 1996;39:600-608.
170. Chuang LM, Lai CS, Yeh JI, Wu HP, Tai TY, Lin BJ. No association between the Gly971 Arg variant of the insulin receptor substrate 1 gene and NIDDM in the Taiwanese population. Diabetes Care 1996;19:446-449.
171. Zhang Y, Wat N, Stratton IM, Warren-Perry MG, Orho M, Groop L, Turner RC. UKPDS 19: Heterogeneity in NIDDM: Separate contributions of IRS-1 and beta 3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations. UK Prospective Diabetes Study. Diabetologia 1996;39:1505-1511.
172. Laakso M, Malkki M, Kekalainen P, Kuusisto J, Deeb SS. Insulin receptor substrate-1 variants in non-insulin-dependent diabetes. J Clin Invest 1994;94:1141-1146.
173. Mori H, Hashiramoto M, Kishimoto M, Kasuga M. Amino acid polymorphisms of the insulin receptor substrate-1 in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1995;80:2822-2826.
174. Ito K, Katsuki A, Furuta M, Fujii M, Tsuchihashi K, Hori Y, Yano Y, Sumida Y, Adachi Y. Insulin sensitivity is not affected by mutation of codon 972 of the human IRS-1 gene. Harm Res 1999;52:230-234.
175. Sigal RJ, Doria A, Warram JH, Krolewski AS. Codon 972 polymorphism in the insulin receptor substrate-1 gene, obesity, and risk of noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:1657-1659.
176. Hart LM, Stolk RP, Dekker JM, Nijpels G, Grobbee DE, Heine RJ, Maassen JA. Prevalence of variants in candidate genes for type 2 diabetes mellitus in The Netherlands: The Rotterdam study and the Hoorn study. J Clin Endocrinol Metab 1999;84:1002-1006.
177. Hager J, Zouali H, Velho G, Froguel P. Insulin receptor substrate (1RS-1) gene polymorphisms in French NIDDM families. Lancet 1993;342:1430.
178. Shimokawa K, Kadowaki H, Sakura H, Otabe S, Hagura R, Kosaka K, Yazaki Y, Akanuma Y, Kadowaki T. Molecular scanning of the glycogen synthase and insulin receptor substrate-1 genes in Japanese subjects with non-insulin-dependent diabetes mellitus. Biochem Biophys Res Commun 1994;202:463-469.
179. Yamada K, Yuan X, Ishiyama S, Shoji S, Kohno S, Koyama K, Koyanagi A, Koyama W, Nonaka K. Codon 972 polymorphism of the insulin receptor substrate-1 gene in impaired glucose tolerance and late-onset NIDDM. Diabetes Care 1998;21:753-756.
180. Rosskopf D, Frey U, Eckhardt S, Schmidt S, Ritz E, Hofmann S, Jaksch M, Muller N, Husing J, Siffert W, Jocke KH. Interaction of the G protein beta 3 subunit T825 allele and the IRS-1 Arg972 variant in type 2 diabetes. Eur J Med Res 2000;5:484-490.
181. Lei HH, Coresh J, Shuldiner AR, Boerwinkle E, Brancati FL. Variants of the insulin receptor substrate-1 and fatty acid binding protein 2 genes and the risk of type 2 diabetes, obesity, and hyperinsulinemia in African-Americans: The Atherosclerosis Risk in Communities Study. Diabetes 1999;48:1868-1872.
182. Clausen J, Hansen T, Bjoerbaek C, Echwald S, Urhammer S, Rasmussen S, Andersen C, Hansen L, Almind K, Winther K, Haraldsdottir J, Borch-Johnsen K, Pedersen O. Insulin resistance: Interactions between obesity and a common variant of the insulin receptor substrate-1. Lancet 1995;346:397-402.
183. Abe H, Yamada N, Kamata K, Kuwaki T, Shimada M, Osuga J, Shionoiri F, Yahagi N, Kadowaki T, Tamemoto H, Ishibashi S, Yazaki Y, Makuuchi M. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 1998;101:1784-1788.
184. Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, Suzuki R, Tsubamoto Y, Komeda K, Nakano R, Miki H, Satoh S, Sekihara H, Sciacchitano S, Lesniak M, Aizawa S, Nagai R, Kimura S, Akanuma Y, Taylor SI, Kadowaki T. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 2000;40:1880-1889.
185. Smith U, Gogg S, Johansson A, Olausson T, Rotter V, Svalstedt B. Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB 2001;15:215-220.
186. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, Groop L. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. New Engl J Med 1989;321:337-343.
187. Lehto M, Stoffel M, Groop L, Espinosa III R, LeBeau M, Bell G. Assignment of the gene encoding glycogen synthase to human chromosome 19, band q13.3. Genomics 1993;15:460-461.
188. Orho M, Nikula-Ijäs P, Schalin-Jäntti C, Permutt M, Groop L. Isolation and characterization of the human muscle glycogen synthase gene. Diabetes 1995;44:1099-1105.
189. Groop LC, Kankuri M, Schalin-Jantti C, Ekstrand A, Nikula-Ijas P, Widen E, Kuismanen E, Eriksson J, Franssila-Kallunki A, Saloranta C, Koskimies S. Association between Polymorphism of the Glycogen Synthase Gene and Non-Insulin-Dependent Diabetes Mellitus. N Engl J Med 1993;328:10-14.
190. Majer M, Mott D, Mochizuki H, Rowles J, Pedersen O, Knowler W, Bogardus C, Prochazka M. Association of the glycogen synthase locus 19q13 with NIDDM in Pima Indians. Diabetologia 1996;39:314-321.
191. Orho-Melander M, Almgren P, Kanninen T, Forsblom C, Groop L. A paired sibling analysis of the XbaI polymorphism in the muscle glycogen synthase gene. Diabetologia 1999;1138-1145.
192. Fenger M, Poulsen P, Beck-Nielsen H, Vaag A. Impact of the Xba1-polymorphism of the human muscle glycogen synthase gene on parameters of the insulin resistance syndrome in a Danish twin population. Diabet Med 2000;17:735-740.
193. St-Onge I, Joanisse DR, Simoneau IA. The stimulation-induced increase in skeletal muscle glycogen synthase content is impaired in carriers of the glycogen synthase XbaI gene polymorphism. Diabetes 2001;50:195-198.
194. Babadjanova G, Allolio B, Beuschlein F, Chuchalin A, Reincke M. Polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus in the Russian population. Metabolism 1997;46:121-122.
195. Kadowaki T, Kadowaki H, Yazaki Y. Polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med 1993;328:1568-1569.
196. Zouali H, Velho G, Froguel P, Kadowaki T, Kadowaki H, Yazaki Y, Groop L, Schalin-Jantti C, Lehto M. Polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med 1993;328:1568-1569.
197. Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev 1999;20:101-135.
198. Hansen L, Echwald SM, Hansen T, Urhammer SA, Clausen JO, Pedersen O. Amino acid polymorphisms in the ATP-regulatable inward rectifier Kir6.2 and their relationships to glucose- and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM. Diabetes 1997;46:508-512.
199. Yamada Y, Kuroe A, Li Q, Someya Y, Kubota A, Ihara Y, Tsuura Y, Seino Y. Genomic variation in pancreatic ion channel genes in Iapanese type 2 diabetic patients. Diabetes/Metabolism Research and Reviews 2001;17:213-216.
200. Sakura H, Wat N, Horton V, Millns H, Turner RC, Ashcroft FM. Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: No association with NIDDM in while Caucasian subjects or evidence of abnormal function when expressed in vitro. Diabetologia 1996;39:1233-1236.
201. Inoue H, Ferrer I, Warren-Perry M, Zhang Y, Millns H, Turner RC, Elbein SC, Hampe CL, Suarez BK, Inagaki N, Seino S, Permutt MA. Sequence variants in the pancreatic islet beta-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: Identification and lack of role in Caucasian patients with NIDDM. Diabetes 1997;46:502-507.
202. Hani EH, Boutin P, Durand E, Inoue H, Permutt MA, Velho G, Froguel P. Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): A meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians. Diabetologia 1998;41:1511-1515.
203. Gloyn AL, Hashim Y, Ashcroft SJ, Ashfield R, Wiltshire S, Turner RC. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabetic Medicine 2001;18:206-212.
204. Nielsen EM, Hansen L, Carstensen B, Echwald SM, Drivsholm T, Glumer C, Thorsteinsson B, Borch-Johnsen K, Hansen T, Pedersen O. The E23K valiant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 2003;52:573-577.
205. Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, Hitman G, Walker M, Levy JC, Sampson M, Halford S, McCarthy M, Hattersley AT, Frayling TM. Large scale association studies of variants in genes encoding the pancreatic b-cell KATP channel subunits Kir 6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003;52:568-572.
206. Love-Gregory L, Wasson J, Lin J, Skolnick G, Suarez B, Permutt MA. An E23K single nucleotide polymorphism in the islet ATP-sensitive potassium channel gene (Kir6.2) contributes as much to the risk of type II diabetes in Caucasians as the PPARgPro12Ala varant. Diabetologia 2002;43:136-137.
207. Schwanstecher C, Meyer U, Schwanstecher M. K(IR)6.2 polymorphism predisposes to type 2 diabetes by inducing overactivity of pancreatic beta-cell ATP-sensitive K(+) channels. Diabetes 2002;51:875-879.
208. Thomas PM, Cote GJ, Wohllk N, Haddad B, Mathew PM, Rabl W, Aguilar-Bryan L, Gagel RF, Bryan J. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 1995;268:426-429.
209. Huopio H, Reimann F, Ashfield R, Komulainen J, Lenko H-L, Rahier J, Vauhkonen I, Kere J, Laakso M, Aschcroft F, Otonkoski T. Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylrea receptor type 1. J Clin Invest 2000;106:897-906.
210. Huopio H, Otonkoski T, Vauhkonen I, Reimann F, Aschcroft FM, Laakso M. A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1. Lancet 2003;361:301-307.
211. Inoue H, Ferrer J, Welling CM, Elbein SC, Hoffman M, Mayorga R, Warren-Perry M, Zhang Y, Millns H, Turner R, Province M, Bryan J, Permutt MA, Aguilar-Bryan L. Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Diabetes 1996;45:825-831.
212. Hani EH, Clement K, Velho G, Vionnet N, Hager J, Philippi A, Dina C, Inoue H, Permutt MA, Basdevant A, North M, Demenais F, Guy-Grand B, Froguel P. Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes 1997;46:688-694.
213. Hansen T, Echwald SM, Hansen L, Moller AM, Almind K, Clausen JO, Urhammer SA, Inoue H, Ferrer J, Bryan J, Aguilar-Bryan L, Permutt MA, Pedersen O. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 1998;47:598-605.
214. van Tilburg JH, Rozeman LB, van Someren H, Rigters-Aris CA, Freriks JP, Pearson PL, Sandkuijl LA, van Haeften TW, Wijmenga C. The exon 16-3t variant of the sulphonylurea receptor gene is not a risk factor for Type II diabetes mellitus in the Dutch Breda cohort. Diabetologia 2000;43:681-682.
215. Hart LM, de Knijff P, Dekker JM, Stolk RP, Nijpels G, van der Does FE, Ruige JB, Grobbee DE, Heine RJ, Maassen JA. Variants in the sulphonylurea receptor gene: Association of the exon 16-3t variant with Type II diabetes mellitus in Dutch Caucasians. Diabetologia 1999;42:617-620.
216. Bell GI, Selby MJ, Rutter WJ. The highly polymorphic region near the human insulin gene is composed of simple tandemly repeating sequences. Nature 1982;295:31-35.
217. Lucassen AM, Juloer C, Beressi J-P, Boitard C, Froguel P, Lathrop M, Bell JI. Susceptibility to insulin dependent diabetes mellitus maps to a 4.1 kb segment of DNA spanning the insulin gene and associated VNTR. Nature Genetics 1993;4:305-310.
218. Bennett ST, Wilson AJ, Esposito L, Bouzekri N, Undlien DE, Cucca F, Nistico L, Buzzetti R, the IMDIAB Group, Bosi E, Pociot F, Nemp J, Cambon-Thomsen A, Pugliese A, Shield JPH, Kinney PA, Bain SC, Polychronakos C, Todd JA. Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele. Nature Genetics 1997;17:350-352.
219. LeStunff C, Fallin D, Bougnères. Paternal transmission of the very common class I INS VNTR alleles predisposes to childhood obesity. Nature Genetics 2001;29:96-99.
220. Lindsay RS, Hanson RL, Wiedrich C, Knowler WC, Bennett PH, Baier LJ. The insulin gene variable number tandem repeat class I/III polymorphism is in linkage disequilibrium with birth weight but not type 2 diabetes in the Pima population. Diabetes 2003;52:187-193.
221. Lucassen AM, Screaton GR, Julier C, Elliott TJ, Lathrop M, Bell JI. Regulation of insulin gene expression by the IDDM associated, insulin locus haplotype. Hum Mol Genet 1995;4:501-506.
222. Vafiadis P, Bennett ST, Colle E, Grabs R, Goodyer CG, Polychronakos C. Imprinted and genotype-specific expression of genes at the IDDM2 locus in pancreas and leucocytes. J Autoimmun 1996;9:397-103.
223. Pugliese A, Zeller M, Fernandez A, Jr. Zalcberg LJ, Bartlett RJ, Ricordi C, Pietropaolo M, Eisenbarth GS, Bennett ST, Patel DD. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997;15:293-297.
224. Undlien DE, Berg JP. Common variants in the regulatory region of the insulin gene are associated with fasting plasma insulin levels in juvenile obesity. Eur J Endocrinol 2001;144:457-459.
225. Huxtable SJ, Saker PJ, Haddad L, Walker M, Frayling TM, Levy JC, Hitman GA, O'Rahilly S, Hattersley AT, McCarthy MI. Analysis of parent-offspring trios provides evidence for linkage and association between the insulin gene and type 2 diabetes mediated exclusively through paternally transmitted class III variable number tandem repeat alleles. Diabetes 2000;49:126-130.
226. Rotwein PS, Chirgwin J, Province M, Knowler WC, Pettitt DJ, Cordell B, Goodman HM, Permutt MA. Polymorphism in the 5′ flanking region of the human insulin gene: A genetic marker for non-insulin-dependent diabetes. N Engl J Med 1983;308:65-71.
227. Bell GI, Karam JH, Rutter WJ. Polymorphic DNA region adjacent to the 5′ end of the human insulin gene. Proc Natl Acad Sci USA 1981;78:5759-5763.
228. Owerbach D, Nerup J. Restriction fragment length polymorphism of the insulin gene in diabetes mellitus. Diabetes 1982;31:275-277.
229. Ong KK, Phillips DI, Fall C, Poulton J, Bennett ST, Golding J, Todd JA, Dunger DB. The insulin gene VNTR, type 2 diabetes and birth weight. Nat Genet 1999;21:262-263.
230. Bouchard C, Perusse L, Chagnon YC, Warden C, Ricquier D. Linkage between markers in the vicinity of the uncoupling protein 2 gene and resting metabolic rate in humans. Hum Mol Genet 1997;6:1887-1889.
231. Esterbauer H, Schneitler C, Oberkofler H, Ebenbichler C, Paulweber B, Sandhofer F, Ladurner G, Hell E, Strosberg AD, Patsch JR, Krempler F, Patsch W. A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 2001;28:178-183.
232. Dalgaard LT, Pedersen O. Uncoupling proteins: Functional characteristics and role in the pathogenesis of obesity and Type II diabetes. Diabetologia 2001;44:946-965.
233. Otabe S, Clement K, Rich N, Warden C, Pecqueur C, Neverova M, Raimbault S, Guy-Grand B, Basdevant A, Ricquier D, Froguel P, Vasseur F. Mutation screening of the human UCP 2 gene in normoglycemic and NIDDM morbidly obese patients: Lack of association between new UCP 2 polymorphisms and obesity in French Caucasians. Diabetes 1998;47:840-842.
234. Wang H, Chu WS, Lu T, Hasstedt SJ, Kern PA, Elbein SC. Uncoupling Protein 2 Polymorphisms in Type 2 Diabetes, Obesity, and Insulin Secretion. Am J Physiol Endocrinol Metab 2004;286:E1-E7.
235. Shiinoki T, Suehiro T, Ikeda Y, Inoue M, Nakamura T, Kumon Y, Nakauchi Y, Hashimoto K. Screening for variants of the uncoupling protein 2 gene in Japanese patients with non-insulin-dependent diabetes mellitus. Metabolism 1999;48:581-584.
236. Kubota T, Mori H, Tamori Y, Okazawa H, Fukuda T, Miki M, Ito C, Fleury C, Bouillaud F, Kasuga M. Molecular screening of uncoupling protein 2 gene in patients with noninsulin-dependent diabetes mellitus or obesity. J Clin Endocrinol Metab 1998;83:2800-2804.
237. Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, Hagen T, Vidal-Puig AJ, Boss O, Kim YB, Zheng XX, Wheeler MB, Shulman GI, Chan CB, Lowell BB. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 2001;105:745-755.